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Abstract
Withanolides are steroidal lactones widespread in Nightshade plants with often potent antiproliferative activities. Additionally, the
structural diversity of this compound class holds much potential for the discovery of novel biological activity. Here, we report two
newly characterised withanolides, named irinans, from Physalis peruviana with highly unusual truncated backbones that resemble
mammalian androstane sex hormones. Based on biomimetic chemical reactions, we propose a model that links these compounds to
withanolide biosynthesis. Irinans have potent antiproliferative activities, that are however lower than those of 4ß-hydroxywithano-
lide E. Our work establishes androwithanolides as a new subclass of withanolides.
Introduction
Traditional medicine has long been a source of inspiration for
modern drug research. An important example is Withania
somnifera, also known as ashwaghanda or Indian ginseng,
which has been used in Ayurvedic medicine to treat a large
variety of ailments [1]. Extensive studies revealed withanolides,
a class of steroidal lactones, to be primarily responsible for the
medicinal effects [1,2]. A large range of pharmacological prop-
erties has been assigned to withanolides, with antiproliferative
activities being the most potent ones [1]. Withanolides have
been also discovered in numerous genera other than Withania,
for example Datura, Dunalis, Iochroma, Jaborosa, Lycium and
Physalis [3], resulting in more than 300 known representatives
[3]. Physalis peruviana is a withanolide producer of particular
relevance as it is widely cultivated for its edible berries [4]. So
far, several withanolides have been reported from P. peruviana
and other Physalis species, most prominently physalins, peru-
lactones and 4ß-hydroxywithanolide E (1) [5-16]. As part of our
ongoing programme focussed on the biochemistry of withano-
lides, our aim was to gain further insights into the withanolide
profile of P. peruviana. Here we report irinans A (2) and B (3),
two unusual truncated withanolides with androstane backbones.
We show that oxidative, but not acidic or basic conditions
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Figure 1: Withanolides from Physalis peruviana. A) Structures of the newly characterised truncated withanolides irinan A (2) and B (3) with an
androstane backbone, together with the known withanolides 1 and 4–6 isolated from P. peruviana. B) P. peruviana plant.
enable conversion of the putative precursor 4ß-hydroxywith-
anolide E (1) to irinan A (2). Based on this intrinsic reactivity
we propose a biosynthetic model that will serve as further guid-
ance for elucidating the enzymatic basis of androstane forma-
tion in plants in the future.
Results and Discussion
To isolate withanolides from P. peruviana, we used a purifica-
tion strategy based on previous reports [17-19]. Nine weeks old
whole P. peruviana plants (140 g) were extracted with
H2O/MeOH (3:1) and divided into fractions soluble in petro-
leum ether, chloroform, and n-butanol, respectively. The
chloroform fraction was further separated by flash chromatogra-
phy on a C18 stationary phase, resulting in three major subfrac-
tions F1–F3. Final purification by preparative HPLC followed
by NMR analysis revealed 4β-hydroxywithanolide E (1) as the
major compound (50 mg) as well as the known metabolites
withanolide E (4), withanolide F (5) and perulactone H (6) by
comparison to literature data (Figure 1) [9,20].
Two additional compounds attracted our attention based on
their unusual 1H NMR spectra (Table 1). Both showed two
multiplets in the olefinic region, which are highly characteristic
for withanolides with A-ring Michael acceptors. However, com-
pared to other withanolides, several signals were missing. Typi-
cally, withanolides show five singlets for methyl groups in the
aliphatic region, as well as the H-22 oxymethine proton of the
lactone moiety. Surprisingly, both compounds showed only two
putative methyl signals, and no signal which might correspond
to H-22. Thus, we reasoned that both unknown compounds
might be truncated withanolide-like compounds.
HRESIMS suggested a sum formula of C19H24O5 for the first
compound, which was supported by the 13C spectrum (Table 1).
By comparing the spectrum to NMR data of other withanolides,
we quickly identified the Michael system in ring A based on
two olefinic protons (δH 6.94 and 6.22 ppm), a secondary
alcohol at C-4 (δH 3.79 ppm), a 5,6-epoxide (δH 3.37 (H-6)),
and a tertiary alcohol at C-14 (δC 80.9 ppm). COSY correla-
tions supported by HMBC analysis (Figure 2A) revealed an
intact ABCD ring system with a substitution pattern identical to
4β-hydroxywithanolide E (1). Only a single, striking difference
was noted: C-17 was shifted from 87.8 to 218.0 ppm, strongly
suggesting the presence of a ketone instead of an alcohol. In
agreement with the predicted sum formula and the absence of
all side chain carbons, this completed the structure of the
first unknown compound, which we named irinan A (2,
Figure 1).
The second unknown compound had a sum formula of
C19H24O3 based on HRESIMS and 13C NMR (Table 1). In
contrast to the first compound, no epoxide and no secondary
alcohol at C-4 was present, in agreement with the different
elemental composition. Instead, 13C NMR indicated a double
bond at C5–C6 (δC 135.7 and 124.3 ppm). Otherwise, all spin
systems and correlations indicated a typical withanolide ABCD
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Table 1: 13C and 1H NMR data (CDCl3, 500 MHz, 298 K) of irinans A (2) and B (3) in comparison to the known compound 4β-hydroxywithanolide E
(1, CDCl3, 400 MHz, 298 K, δ in ppm, J in Hz). For carbon numbering see Figure 1 and Figure 2.
13C 1H
position 1 2 3 1 2 3
1 201.9 202.0 203.8 – – –
2 133.2 132.3 128.1 6.22 (1H, d, 9.9) 6.22 (1H, d, 10.0) 5.91 (1H, ddd, 10.0, 3.1, 1.2)
3 141.4 142.1 145.3 6.92 (1H, dd, 9.9, 6.1) 6.94 (1H, dd, 10.0, 5.8) 6.79 (1H, ddd, 10.0, 5.0, 2.6)
4 70.4 69.9 33.6 3.74 (1H, d, 6.1) 3.79 (1H, dd, 5.8, 2.4) 3.31 (1H, dddddd, 21.3, 2.8,
2.8, 2.8, 2.8, 2.8)a
2.88 (1H, dd, 21.2, 4.9)
5 64.2 63.9 135.7 – – –
6 63.1 63.1 124.3 3.28 (1H, br s) 3.37 (1H, m) 5.64 (1H, dt, 5.7, 2.0)
7 26.0 24.9 24.1 2.03 (2H, m) 2.11 (1H, dt, 14.2, 3.1)
1.84 (1H, ddd, 14.1, 11.7,
1.4)
2.08 (1H, m)
1.95 (1H, m)
8 34.3 32.6 35.5 1.83 (1H, m) 1.90 (1H, m) 1.88 (1H, m)
9 36.7 38.1 37.1 1.69 (1H, m) 1.51 (1H, m) 2.10 (1H, m)
10 47.9 47.8 50.9 – – –
11 21.5 20.4 21.6 1.72 (1H, m)
1.56 (1H, m)
1.91 (1H, m)
1.46 (1H, m)
2.34 (1H, m)
1.52 (1H, m)
12 29.8 24.3 25.0 2.25 (1H, m)
1.28 (1H, m)
1.66 (1H, d, 13.2)
1.55 (1H, m)
1.86 (1H, m)
1.63 (1H, m)
13 54.6 52.6 52.5 – – –
14 81.9 80.9 81.0 – – –
15 32.5 30.0 29.9 1.66 (1H, m)
1.59 (1H, m)
1.92 (2H, m) 1.96–1.85 (2H, m)
16 38.0 33.1 33.1 2.72 (1H, m)
1.45 (1H, m)
2.44 (1H, ddd, 18.9, 7.6, 4.1)
2.33 (1H, dt, 18.8, 8.8)
2.35–2.46 (2H, m)
17 87.8 218.0 218.5 – – –
18 20.4 17.9 18.1 1.07 (3H, s) 1.01 (3H, s) 1.05 (3H, s)
19 16.9 17.8 19.2 1.42 (3H, s) 1.45 (3H, s) 1.27 (3H, s)
20 79.2 – – – – –
21 19.8 – – 1.42 (3H, s) – –
22 79.7 – – 4.88 (1H, dd, 11.8, 5.3) – –
23 34.4 – – 2.51 (2H, m) – –
24 150.8 – – – – –
25 121.6 – – – – –
26 166.0 – – – – –
27 12.5 – – 1.88 (3H, s) – –
28 20.8 – – 1.94 (3H, s) – –
14-OH n.d. 1.41 (1H, br s) 1.41 (1H, br s)
4-OH n.d. 2.57 (1H, d, 2.50) -
aApparent dsext. See Figure S19 (Supporting Information File 1) for details. n.d. not detected.
ring system. Again, a carbon with a distinct downfield shift of
218.4 ppm was found, demonstrating the presence of a ketone
at C-17. Highly unusually, H-4β appeared as a doublet of
sextets (1:5:10:10:5:1) (dsext) in the 1H NMR spectrum. This
multiplet was explained as “dddddd” by a total of six COSY
correlations (Figure S19, Supporting Information File 1). The
resulting compound was named irinan B (3, Figure 1). A com-
pound of putatively identical structure was isolated from
P. peruviana before, but only fragmentary physicochemical
data has been reported so far [14].
To elucidate the relative stereochemistry of irinans A (2) and B
(3), we analysed NOESY data (Figure 2). In the case of irinan
A (2), the β configuration of OH-4 was deduced by the NOESY
correlation OH-4/CH3-19. OH-14 was assigned as α based on
the correlations OH-14/H-12α and H-9/H-12α. The 5,6-epoxide
was determined as β by a correlation from H-6 to H-3. These
assignments are in complete agreement with the relative stereo-
chemistry of 4ß-hydroxywithanolide E (1). In irinan B, the con-
figuration of OH-14 could not be unambiguously inferred from
NOE data due to the signal overlap of H-15 with H-12 and
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Figure 2: Key NMR correlations. (A) COSY and HMBC correlations for irinan A (2). (B) COSY and HMBC correlations for irinan B (3). (C) Key
NOESY correlations for irinan A (2). (D) Key NOESY correlations for irinan B (3).
other protons. As an alternative, OH-14 α configuration was
deduced from the chemical shifts of C-12 and C-9, which expe-
rience a strong shielding γ-gauche effect for OH-14α configura-
tions [21]. These data indicate a relative stereochemistry of
irinan B matching withanolide F (5).
Irinans represent highly unusual withanolide derivatives, as
they lack the side-chain lactone ring that is a common struc-
tural feature of virtually all known withanolides [3], but pos-
sess an androstane backbone instead. While androstanes such as
androsterone (7) are well-known human sex hormones
(Figure 3A) [22], their occurrence in plants is rare [23-26].
Only a single withanolide androstane has been fully charac-
terised before, cinedione (8), isolated from Physalis cineras-
cens (Figure 3A) [23]. We propose the name androwithano-
lides for this withanolide subclass, which so far appears to be
characteristic of Physalis species.
The biosynthesis of androstanes in mammals requires three
enzymatic steps starting from cholesterol (9, Figure 3B) [27].
Cholesterol (9) is converted to pregnenolone (10) by the
cytochrome P450 cholesterol side-chain cleavage enzyme
(P450scc), which cleaves the C20–C22 bond [27]. Then, the
bifunctional P450c17 acts as a 17α-hydroxylase and 17,20-lyase
to give rise to androstanes [27]. Related enzymes have not been
reported from plants. We searched transcriptome data of
P. peruviana for putative homologues of these enzymes [28].
The best hits only had amino acid sequence identities of
22–28%, indicating that no P450 enzymes of these clans exist in
P. peruviana. Although enzymes with similar catalytic activity
might have evolved convergently in plants, the different substi-
tution pattern in the side chain suggests that a side-chain
cleavage mechanism distinct from mammals is involved. While
the order of oxidative steps in withanolide biosynthesis is still
completely elusive [29], we propose that this fragmentation
occurs at a late stage, when most typical withanolide functional-
isations have already been introduced. Indeed, irinan A (2),
irinan B (3) and cinedione (8) can be directly linked to the
known withanolides 4ß-hydroxywithanolide E (1), withanolide
F (5) and withanolide S [23], respectively (Figure S20, Support-
ing Information File 1). If the fragmentation occurred early in
the biosynthesis, this would imply that several biosynthetic en-
zymes have to tolerate substrates without the lactone side chain.
We therefore propose that the side-chain cleavage enzyme in
withanolide biosynthesis acts at a late stage, using common
pathway end products such as 4ß-hydroxywithanolide E (1) as
its substrates. Two mechanisms are conceivable for this trans-
formation (Figure 3C): A non-oxidative Grob fragmentation
could make use of a push–pull mechanism between C-17 and
C-22, building on acid–base catalysis. Alternatively, an en-
zyme could cleave the C17–C20 diol oxidatively. Several P450
enzymes have been reported to be capable of cleaving diols,
presumably via a ferric peroxo intermediate (Figure 3C)
[30,31].
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Figure 3: Structures and biosynthesis of androstanes. (A) Androstane backbone and androsterone (7) as a typical mammalian sex hormone. Cine-
dione (8) is the only other fully characterised androwithanolide known. (B) Biosynthesis of androstanes in mammals. (C) Possible cleavage mecha-
nisms involved in androwithanolide biosynthesis in plants.
To gain further insights into the biosynthetic route and to
exclude that androwithanolides are isolation artefacts [32], we
exposed 4ß-hydroxywithanolide E (1) as the likely precursor to
irinan A (2) to various chemical conditions (Figure 4). In
general, 1 was stable in all solvents tested, namely chloroform,
methanol, DMSO and acetonitrile (data not shown). Treatment
with acid at pH 3 caused no reaction at all when heating up to
70 °C (Figure 4A). At pH 0, several unidentified compounds
appeared, but not irinan A (2). In basic conditions, only a single
unidentified product was formed at pH 11 and 70 °C. Next, we
tested whether 1 could be oxidatively cleaved [33]. Incubation
of 1 with NaIO4 at room temperature did not result in any reac-
tion (data not shown). However, although it has been reported
that periodates are not capable of cleaving ditertiary glycols
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Figure 4: Intrinsic reactivity of 4ß-hydroxywithanolide E (1) under acidic/basic and oxidative conditions, respectively. (A) LC–MS chromatograms (ELS
detection) of 1 incubated at different pH values. (B) LC–MS chromatograms (UV detection at 200–400 nm) of 1 treated with different oxidative
reagents. The formation of 2 in the NaIO4 reaction was confirmed by NMR analysis. See also Figure S21 in Supporting Information File 1 for extracted
ion chromatograms (EICs).
Table 2: Antiproliferative activities in different cell lines. Data indicate EC50 values ± SD in µM. A549 = human lung carcinoma; L929 = mouse fibro-
blast; KB-3-1 = human cervix carcinoma; MCF-7 = human breast cancer cell line.
Compound A549 L929 KB-3-1 MCF-7
4ß-hydroxywithanolide E (1) 3.74 ± 0.50 0.27 ± 0.30 1.11 ± 0.98 10.65 ± 6.18
irinan A (2)a 5.01 ± 5.27 2.29 ± 0.88 4.62 ± 5.76 17.88 ± 7.27
irinan B (3)b 3.45 ± 1.91 1.68 ± 1.78 2.40 ± 2.32 13.56 ± 9.18
staurosporine (positive control) 1.19 ± 0.99 <0.003 0.04 ± 0.01 0.16 ± 0.02
auranofin (positive control) >7.03 2.35 ± 0.83 1.59 ± 0.37 2.06 ± 0.60
aEstimated 90% purity based on 1H NMR. bEstimated 80% purity based on 1H NMR.
[33,34], we noted formation of small quantities of irinan A (2)
when performing the reaction at 70 °C (Figure 4B and Figure
S21 in Supporting Information File 1). The identity of irinan A
(2) was verified by isolation of the corresponding compound by
preparative HPLC (4% yield) followed by NMR analysis. This
result confirms our NMR-based stereochemical assignment and
unambiguously links irinan A (2) to 4ß-hydroxywithanolide E
(1). We also performed an oxidative cleavage reaction with cat-
alytic amounts of MoO2(acac)2 in DMSO as described by
García et al. [34], which also led to the formation of trace
amounts of irinan A (2). Our experiments suggest that irinan A
(2) and most likely all androwithanolides are not isolation arte-
facts but true natural products, which require an oxidative en-
zyme to facilitate the C–C bond cleavage. Future studies will
shed light on the enzymatic basis of androwithanolide forma-
tion.
Considering the potent bioactivities of androstanes as well as
withanolides, we wondered whether the loss of the side-chain
lactone would negatively impact the antiproliferative activity.
Irinan A (2) and B (3) together with 4ß-hydroxywithanolide E
(1) as a positive control were evaluated against a panel of four
cell lines (Table 2). In our assays we observed decreasing activ-
ities during the third and fourth replicates, resulting in large
standard deviations and potentially indicating limited stability
of these compounds. Nonetheless, EC50 values of 4ß-hydroxy-
withanolide E (1) were in good agreement with previously
published values [14,35,36]. Irinans A (2) and B (3) were 1.3 to
10-fold less active than 4ß-hydroxywithanolide E (1), with the
exception of irinan B (3) in A549 cells, which was equipotent.
However, irinan A (2) and B (3) samples had a purity of 90%
and 80%, respectively. We therefore cannot exclude that
unidentified impurities, which could not be removed by
repeated preparative HPLC, obscure the true EC50 values of
irinans. We conclude that irinans possess potent antiprolifera-
tive activity, that is however reduced compared to 4ß-hydroxy-
withanolide E (1). Our results demonstrate the importance of
the lactone side chain for bioactivity.
Conclusion
We have discovered and characterised irinans A and B,
two new withanolides from P. peruviana with truncated back-
bones. They resemble mammalian sex hormones of the
androstane class. The relative stereochemistry was elucidated
based on NOESY analysis. Chemical studies support a model
that these compounds are formed by an oxidative process. We
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propose the name androwithanolides for this withanolide
subclass.
Experimental
General experimental procedures
Seeds of Physalis peruviana were obtained from FloraSelf,
Sperli and Quedlinburger Saatgut. Plants were initially grown in
seed starter soil (Kölle’s Beste Anzuchterde) and later trans-
ferred to potting soil (Kölle’s Beste Pflanzerde). Plants were
grown under LED il lumination (SANlight S2W) at
350 µmol s−1 m−2 PPFD with a 12 h photoperiod and at
18–25 °C without temperature and humidity control. Plants
were watered twice per week with tap water as needed.
NMR spectra were recorded using Bruker AscendTM 400 or
DRX 500 MHz spectrometers operating at 400 and 500 MHz
for 1H NMR and at 100 and 125 MHz for 13C NMR where
CDCl3 was used as solvent. Chemical shifts were referenced
relative to the residual solvent signal of CDCl3 (δH = 7.26 ppm,
δC = 77.16 ppm) and expressed in δ values (ppm), with cou-
pling constants reported in Hz. Analysis was conducted with
TopSpin (Version 4.0.6, Bruker). ATR-IR analysis was per-
formed for the range of 400–4000 cm−1 using a Shimadzu
IRAffinity 1S spectrometer with samples dissolved in chloro-
form. Optical rotations were measured with a Perkin Elmer 341
polarimeter. Using methanol as solvent, the wavelength for
maximum absorption was determined on a Jasco V-630 spec-
trophotometer. Flash purification was performed on a Biotage
Isolera One using columns described below. HRMS measure-
ments were carried out on a Waters Alliance 2695 HPLC
coupled to a Micromass LCT Premier mass spectrometer.
For analytical and preparative LC–MS a Waters instrument was
used consisting of a Waters 2767 autosampler, Waters 2545
pump system, Waters 2998 diode array detector, Waters 2424
ELS detector, and a Waters SQ Detector 2 for mass spectrome-
try in ESI+ and ESI– modes between m/z 150 and 1000. In ana-
lytical mode, a Phenomenex Kinetex column (2.6 µm, C18,
100 Å, 4.6 × 100 mm) was used with a gradient of [solvent A:
H2O + 0.05% formic acid; solvent B: acetonitrile + 0.045%
formic acid; gradient: 10% to 90% B over 10 min, 1 mL/min].
Samples were dissolved to a concentration of 10 mg/mL in
MeOH and 20 µL injected. In preparative mode, a Phenomenex
Kinetex Axia column (5 µm, C18, 100 Å, 21.2 × 250 mm)
equipped with a Phenomenex Security Guard precolumn (Luna,
C5, 300 Å) was used in combination with the separation
gradient described below.
Extraction and isolation of withanolides
140 g of 9 weeks old, whole Physalis peruviana plants were
frozen in liquid nitrogen and ground to a fine powder. The
powder was extracted with 500 mL H2O/MeOH (3:1) at room
temperature for 3 h. After filtration and evaporation of the sol-
vent under reduced pressure, the crude extract was resuspended
in 300 mL H2O and defatted with 300 mL petroleum ether. The
remaining aqueous layer was further extracted with 2 × 300 mL
CHCl3 followed by 2 × 300 mL n-BuOH. This resulted in a
660 mg petroleum ether fraction, 386 mg CHCl3 fraction and
1174 mg n-BuOH fraction.
The CHCl3 fraction was separated via reversed-phase flash
chromatography (Biotage SNAP KP-C18-HS 30 g column)
with a H2O/MeOH gradient. Samples were adsorbed onto Celite
under reduced pressure for dry loading. A gradient from 30% to
95% MeOH was used. Fractions were pooled guided by UV
maximum absorbance to form main fraction F1 (subfractions
1–21, 102 mg), F2 (subfractions 22–31, 12 mg) and F3
(subfractions 32–45, 48 mg). No withanolides were detected in
F2 based on LC–MS analysis and therefore discarded.
Fraction F1 was further separated by preparative LC–MS.
The sample was dissolved in MeOH to a concentration of
15 mg/mL. 100 µL was injected per run. A separation gradient
was used [solvent A: H2O + 0.05% formic acid; solvent B:
acetonitrile + 0.045% formic acid; gradient: 10% to 90% B over
10 min, 20 mL/min]. The post-column flow was split
(100:1) and the minority flow made up to 1 mL/min with
MeOH + 0.045% formic acid for in-line analysis by UV, ELSD
and MS. The majority flow was collected. The following peaks
were collected and identified by NMR: tR = 5.8–6.0 min (irinan
A (2), 6 mg); 7.2–8.0 min (4β-hydroxywithanolide E (1),
49 mg); 9.0–9.2 min (irinan B (3), 1 mg). The collected frac-
tions were evaporated under reduced pressure using a Christ
RVC 2-25 CDplus rotational vacuum concentrator.
Main fraction F3 was also separated by preparative LC–MS
as described above, yielding the known compounds withano-
lide E (4) (tR = 7.3–7.6 min, 6 mg), perulactone H (6)
( tR  =  7 .6–7.8  min,  9  mg)  and wi thanol ide  F (5 )
(tR = 7.8–8.5 min, 9 mg) which were identified by NMR [20].
Analytical data
4β-Hydroxywithanolide E (1) was isolated as a white crys-
talline powder. NMR data of 1 is listed in Table 1. All spectros-
copic properties matched literature data [20].
Irinan A (2): white crystalline powder; [α]D20 +10.48 (β = 0.62;
MeOH); UV (MeOH) λmax (log ε) 239 nm (3.93); IR (ATR,
CHCl3) νmax: 3460, 2967, 2930, 1734, 1674, 1454, 1373, 1092,
1036, 986, 922, 754 cm−1; for 1H and 13C data see Table 1;
HRESIMS m/z: [M + Na]+ calcd for C19H24O5Na+, 355.1516;
found, 355.1519.
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Irinan B (3): white crystalline powder; [α]D20 –10.00 (β = 0.06;
MeOH); UV (MeOH) λmax (log ε) 251 nm (3.94); IR (ATR,
CHCl3) νmax: 3402, 2955, 2930, 1682, 1383, 1259, 1215, 1136,
1088, 1016, 966, 806, 748 cm−1; for 1H and 13C data see
Table 1; HRESIMS m/z: [M + Na]+ calcd for C19H24O3Na+,
323.1618; found, 323.1626
BLAST search of known androstane
biosynthesis enzymes
The known androstane biosynthesis enzymes Homo sapiens
P450scc (UniProtKB accession P05108) and Homo sapiens
P450c17 (P05093) were used to search reported Physalis peru-
viana transcriptome data [28] via the tBLASTn algorithm. Both
enzymes yielded several full-length hits with amino acid se-
quence identities of 22–28%.
Oxidative cleavage of 4β-hydroxywithanolide
E (1) to irinan A (2) by NaIO4
57.8 mg of NaIO4 (270.2 µmol, 7.0 equiv) in 400 µL hot H2O
was added to 19.4 mg 4ß-hydroxywithanolide E (1, 38.6 µmol,
1.0 equiv) in 1 mL MeOH. The reaction was incubated at 70 °C
for 72 h in a heat block with shaking at 1000 rpm. After that
time a peak with m/z 315 corresponding to [M + H − H2O]+
with a retention time of 3.5 min was observed by LC–MS,
co-eluting with authentic irinan A (2). The reaction mixture was
separated by preparative LC–MS as described above to give a
white crystalline powder (0.5 mg, 4%), which was confirmed to
be irinan A (2) by 1H NMR spectroscopy.
Oxidative cleavage of 4β-hydroxywithanolide
E (1) to irinan A (2) by MoO2(acac)2
2 µL of a MoO2(acac)2 stock solution in DMSO (100 µg/µL,
0.6 µmol, 0.02 equiv) was added to 14.6 mg hydroxywithano-
lide E (1, 29.0 µmol, 1.0 equiv) in 100 µL DMSO. The reaction
was incubated at 130 °C for 3 h in an oil bath with stirring at
400 rpm. After that time a peak with m/z 315 corresponding to
[M + H − H2O]+ with a retention time of 3.5 min was observed,
co-eluting with authentic irinan A (2). H2O (5 mL) and CHCl3
(5 mL) were added to the reaction mixture. The layers were
separated and the aqueous phase was extracted with chloroform
(3 × 5 mL). Combined organic layers were washed with
water (5 mL), dried over MgSO4, filtered and the solvent was
evaporated under reduced pressure. The resulting crude reac-
tion product was then analysed by analytical HPLC as de-
scribed above.
Antiproliferative assays
The effect of compounds on cell viability was probed with a
WST-1 test using the procedure of Ishiyama et al. [37] as modi-
fied by Sasse et al. [38]. The following cell lines were used:
mouse fibroblast cell line L929 (DSM ACC 2), human cervix
carcinoma cell line KB-3-1 (DSM ACC 158), the human lung
carcinoma cell line A549 (DSMZ ACC 107) and human breast
cancer cell line MCF-7 (DSM ACC 115). The subconfluent
cells were briefly washed with Earle’s Balanced Salt Solution
(Gibco) without Ca and Mg, trypsinized and re-suspended in
Dulbecco’s modified eagle’s medium that contained 5% fetal
bovine serum (FBS; L929, KB-3-1, A549) or Roswell Park
Memorial Institute medium that contained 5% FBS,
0.5% Minimum Essential Medium Non-Essential Amino Acids,
Gibco (MEM NEAA), 0.5% GlutaMAX (Gibco) and insulin at
5 μg/mL (MCF-7). 25 µL of serial dilutions of the test com-
pounds (64–0.06 µg/mL, that were made with a pipetting robot
(epMotion, Eppendorf, Hamburg, Germany), were added to
25 μL aliquots of a cell suspension (1500 cells for KB-3-1,
L929 and A549, 3000 cells for MCF-7) in 384 well microtiter
plates. Blank and solvent controls were incubated under iden-
tical conditions. After an incubation period of 5 days, 3 μL
WST-1 (ready to use solution by Roche) was added. The incu-
bation time of the plates at 37 °C varied between the cell lines
from 20 min for KB-3-1 and A549, L929 for 30 min, and 2 h
for MCF-7 before measuring absorbance at 450 nm (reference
600 nm) with an Infinite 200 PRO plate reader (Tecan,
Männedorf, Switzerland). As positive control compounds,
Auranofin and Staurosporin were applied. The absorbance of
the solvent control was set to 100%. The EC50 values were de-
termined with Sigma Plot. All data are average values from four
biological replicates.
Supporting Information
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